ClinicalTrials.gg
CompletedNCT05470881PRO-201Updated Feb 5, 2026Results posted

Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201

A Phase 1 interventional study of Atropine Sulfate in Myopia, sponsored by Laboratorios Sophia S.A de C.V.. Completed at 1 site in Mexico. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Laboratorios Sophia S.A de C.V. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
52nd of 54
29 · median 144
Started
2022
with 4 others
Phase 1
8 of 54
none open now
Registered
26th of 54
by date
Lead sponsor
2 of 54
Laboratorios Sophia S.A de C.V.

Among the 54 studies testing atropine in Myopia, this one is the 52nd largest by enrollment, is one of 5 that started in 2022, is one of 8 in phase 1, and was the 26th registered.

Myopia

1,163 studies on the registry are indexed under Myopia; 227 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger; 84 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

Evaluation of the safety and tolerability of PRO-201 (0.01% sulfate atropine) after its instillation on the ocular surface of healthy volunteers through the following variables: unexpected adverse events incidence and photophobia (primary outcome variables); as well as pupillary diameter, expected adverse events incidence, best near corrected visual acuity (BNCVA), best corrected visual acuity (BCVA), intraocular pressure (IOP), corneal and conjunctival staining, heart rate, blood pressure and ocular confort index (OCI),

Read the detailed description

A total of 29 healthy volunteers will be enrolled in this study. They will receive one drop of the investigation product PRO-201 (0.01% atropine sulfate) once a day (QD) for a total of 14 days on both eyes. A final safety call will be performed one week after the last day of product application.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being clinically healthy
  • Ability to voluntarily sign an form (ICF).
  • Ability and willingness to comply with the scheduled visits according to the intervention plan and other procedures of the study.
  • Age between 18 and 35.
  • Absence of history of contact lens use.
  • Women of childbearing age must agree to continue (starting ≥ 30 days previous to the ICF) the use of a hormonal method of a intrauterine device (IUD) during the period of the study.
  • Best corrected visual acuity (BVCA) of at least 20/30 (logMAR 0.2) or better in both eyes.
  • Best near corrected visual acuity (BNVCA) of at least 20/25 (logMAR 0.1) or better in both eyes.
  • Presenting vital signs within normal parameters.
  • Presenting an IOP ≥10 and ≤ 21 mmHg

Exclusion criteria

Exclusion Criteria:

  • Using any kind of ophthalmic topical products.
  • Presenting known allergy or intolerance to any ingrediente of atropine eyedrops or any other derivatives of antimuscarinic agents.
  • Using any medication of herbolary products (plant extracts, infusions, naturist preparations, homeopathy, etc) through any route of administration
  • For women: being pregnant, breastfeeding or planning to get pregnant during the period of the study.
  • Having participated in any clinical study 90 days prior to the inclusion in this study.
  • Having participated in this clinical study.
  • Inability to follow the lifestyle considerations of this study.
  • History of any chronic degenerative disease, including diabetes and hypertension.
  • Presenting active inflammatory or infectious diseases when entering this study.
  • Presenting unresolved lesions or trauma when entering this study.
  • History of any ocular surgery.
  • History of any surgery, non-ocular, within the previous 3 months of entering this studies.
  • Being or having an direct family member (spouse, parent/legal guardian, sibling, etc) as employee of the investigation site or the sponsor, who participates directly in this study.

Elimination criteria:

  • Withdraw of ICF.
  • Adverse event, related or not to the investigation product, that according to the principal investigator and/or the sponsor may affect the integrity of the patient to continue safely with the study's procedures.
  • or lack of tolerance to any of the ingredients used during the study's procedures (fluorescein, lissamine green, tetracaine, etc)
  • Hypersensitivity or lack of tolerance to the investigation product.
  • Presenting an adherence to treatment \< 90%, as determined through the subjects diary.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    PRO-201

    A total of 29 anticipated healthy volunteers will be exposed to the investigation product.

    Drug: Atropine Sulfate

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Unexpected Adverse Events

    The number of adverse events presented that are not previously described / known for the active substance in this pharmaceutic form and concentration.

    Time frame: Through Day 21 ± 1 (Safety Call)

  2. Number of Patients With Photophobia

    The number of cases of photophobia.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

Secondary outcomes

  1. Pupillary Diameter

    Measurement of pupillary diameter after exposure to the investigation product.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  2. Percentage of Expected Adverse Events

    The percentage of adverse events presented that are expected, or previously described / known for the active substance in this pharmaceutic form and concentration.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit), 21 ± 1 (Safety Call)

  3. Measurement of the Change in Best Near Corrected Visual Acuity (BCNVA)

    The change in BCNVA after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

Other outcomes

  1. Changes in Intraocular Pressure (IOP)

    The change in IOP after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  2. Number of Cases With Corneal and Conjunctival Staining With Fluorescein

    It was graded according to the Sjögren's International Clinical Collaboration Alliance (SICCA) Ocular Staining Score (CTO). According to the CTO, grade 0 corresponds to the absence of punctate epithelial erosions (PEE); grade 1 is defined as the presence of 1-5 EEPs; grade 2 corresponds to 6-30 EEP; and \>30 EEP will be classified as grade 3. Additionally, one qualification point will be added if: 1) EEP is present in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches, including linear staining, are observed. A higher score is a worse outcome.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  3. Measurement of Vital Signs (Systolic Blood Pressure)

    The change in blood pressure after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  4. Measurement of Vital Signs (Heart Rate)

    The change in heart rate after exposure to investigation product, compared to basal value.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

  5. Value of the Ocular Comfort Index (OCI) Questionnaire.

    It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100). A higher score is a worse outcome. Similar to the index for ocular surface diseases, the ocular comfort index (OCI) evaluates symptoms. The ICO contains 6 items that focus on the discomfort associated with the ocular surface. Each of these questions has two parts, which inquire separately the frequency and severity of the symptoms. The evaluator will deliver the questionnaire to the subject and allow the subject to answer it calmly without any pressure and / or coercion, will only assist him if he has difficulty understanding any of the questions.

    Time frame: Days: 1 (Basal Visit), 16 ± 1 (Final Visit)

  6. Number of Cases With Corneal and Conjunctival Staining With Lissamine Green

    It was graded according to the Sjögren's International Clinical Collaboration Alliance (SICCA) Ocular Staining Score (CTO). According to the CTO, grade 0 corresponds to the absence of punctate epithelial erosions (PEE); grade 1 is defined as the presence of 1-5 EEPs; grade 2 corresponds to 6-30 EEP; and \>30 EEP will be classified as grade 3. Additionally, one qualification point will be added if: 1) EEP is present in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches, including linear staining, are observed. A higher score is a worse outcome.

    Time frame: Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)

07

Results

Posted Feb 5, 2026

Participant flow

Participant flow — Overall Study
MilestonePRO-201
Started29
Completed27
Not completed2
Withdrew: Adherence under 90%2

Outcome measures

PrimaryNumber of Unexpected Adverse Events

The number of adverse events presented that are not previously described / known for the active substance in this pharmaceutic form and concentration.

Time frame:
Through Day 21 ± 1 (Safety Call)
Reported as:
Number · adverse events
Number of Unexpected Adverse Events
adverse eventsPRO-201
Number of Unexpected Adverse Events41
PrimaryNumber of Patients With Photophobia

The number of cases of photophobia.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Count of participants · Participants
Number of Patients With Photophobia
ParticipantsPRO-201
Basal Visit — Photophobia0
Basal Visit — No Photophobia29
Visit 1 — Photophobia5
Visit 1 — No Photophobia24
Final visit — Photophobia2
Final visit — No Photophobia27
SecondaryPupillary Diameter

Measurement of pupillary diameter after exposure to the investigation product.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Mean · mm
Pupillary Diameter
mmPRO-201
BV pupillary diameter3.44 ± 0.44
V1 pupillary diameter3.95 ± 0.60
FV pupillary diameter3.94 ± 0.52
SecondaryPercentage of Expected Adverse Events

The percentage of adverse events presented that are expected, or previously described / known for the active substance in this pharmaceutic form and concentration.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit), 21 ± 1 (Safety Call)
Reported as:
Number · percentage
Percentage of Expected Adverse Events
percentagePRO-201
Percentage of Expected Adverse Events92.7
SecondaryMeasurement of the Change in Best Near Corrected Visual Acuity (BCNVA)

The change in BCNVA after exposure to investigation product, compared to basal value.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Mean · LogMAR (Snellen Chart)
Measurement of the Change in Best Near Corrected Visual Acuity (BCNVA)
LogMAR (Snellen Chart)PRO-201
BV BCNVA0.00 ± 0.02
V1 BCNVA0.00 ± 0.02
FV BCNVA0.01 ± 0.02
Other pre-specifiedChanges in Intraocular Pressure (IOP)

The change in IOP after exposure to investigation product, compared to basal value.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Mean · mmHg
Changes in Intraocular Pressure (IOP)
mmHgPRO-201
VB IOP14.67 ± 2.67
V1 IOP14.04 ± 1.91
FV IOP14.02 ± 2.32
Other pre-specifiedNumber of Cases With Corneal and Conjunctival Staining With Fluorescein

It was graded according to the Sjögren's International Clinical Collaboration Alliance (SICCA) Ocular Staining Score (CTO). According to the CTO, grade 0 corresponds to the absence of punctate epithelial erosions (PEE); grade 1 is defined as the presence of 1-5 EEPs; grade 2 corresponds to 6-30 EEP; and \>30 EEP will be classified as grade 3. Additionally, one qualification point will be added if: 1) EEP is present in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches, including linear staining, are observed. A higher score is a worse outcome.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Number · Eyes (right)
Number of Cases With Corneal and Conjunctival Staining With Fluorescein
Eyes (right)PRO-201
BV corneal and conjunctival staining with fluorescein : Grade 027
BV corneal and conjunctival staining with fluorescein : Grade 10
V1 corneal and conjunctival staining with fluorescein : Grade 026
V1 corneal and conjunctival staining with fluorescein : Grade 11
FV corneal and conjunctival staining with fluorescein : Grade 026
FV corneal and conjunctival staining with fluorescein : Grade 11
Other pre-specifiedMeasurement of Vital Signs (Systolic Blood Pressure)

The change in blood pressure after exposure to investigation product, compared to basal value.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Mean · mmHg
Measurement of Vital Signs (Systolic Blood Pressure)
mmHgPRO-201
BV Systolic Blood Pressure119.74 ± 8.73
V1 BV Systolic Blood Pressure120.96 ± 6.14
FV BV Systolic Blood Pressure119.41 ± 7.48
Other pre-specifiedMeasurement of Vital Signs (Heart Rate)

The change in heart rate after exposure to investigation product, compared to basal value.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Mean · pulse per minutes
Measurement of Vital Signs (Heart Rate)
pulse per minutesPRO-201
BV Heart Rate70.93 ± 6.62
V1 Heart Rate73.15 ± 9.51
FV Heart Rate74.93 ± 8.11
Other pre-specifiedValue of the Ocular Comfort Index (OCI) Questionnaire.

It is a questionnaire designed to measure the irritation of the ocular surface with Rasch analysis to produce estimates on a linear scale of intervals (ratings: 0-100). A higher score is a worse outcome. Similar to the index for ocular surface diseases, the ocular comfort index (OCI) evaluates symptoms. The ICO contains 6 items that focus on the discomfort associated with the ocular surface. Each of these questions has two parts, which inquire separately the frequency and severity of the symptoms. The evaluator will deliver the questionnaire to the subject and allow the subject to answer it calmly without any pressure and / or coercion, will only assist him if he has difficulty understanding any of the questions.

Time frame:
Days: 1 (Basal Visit), 16 ± 1 (Final Visit)
Reported as:
Mean · scores on a scale
Value of the Ocular Comfort Index (OCI) Questionnaire.
scores on a scalePRO-201
BV OCI24.93 ± 9.46
FV OCI25.05 ± 10.39
Other pre-specifiedNumber of Cases With Corneal and Conjunctival Staining With Lissamine Green

It was graded according to the Sjögren's International Clinical Collaboration Alliance (SICCA) Ocular Staining Score (CTO). According to the CTO, grade 0 corresponds to the absence of punctate epithelial erosions (PEE); grade 1 is defined as the presence of 1-5 EEPs; grade 2 corresponds to 6-30 EEP; and \>30 EEP will be classified as grade 3. Additionally, one qualification point will be added if: 1) EEP is present in the central portion of the cornea with a diameter of 4mm; 2) filaments are observed and 3) confluent staining patches, including linear staining, are observed. A higher score is a worse outcome.

Time frame:
Days: 1 (Basal Visit), 7 ± 1 (Visit 1), 16 ± 1 (Final Visit)
Reported as:
Number · Eyes (right)
Number of Cases With Corneal and Conjunctival Staining With Lissamine Green
Eyes (right)PRO-201
BV Corneal and conjunctival staining with lissamine green : Grade 027
BV Corneal and conjunctival staining with lissamine green : Grade 10
BV Corneal and conjunctival staining with lissamine green : Grade 20
V1 Corneal and conjunctival staining with lissamine green : Grade 023
V1 Corneal and conjunctival staining with lissamine green : Grade 12
V1 Corneal and conjunctival staining with lissamine green : Grade 22
FV Corneal and conjunctival staining with lissamine green : Grade 026
FV Corneal and conjunctival staining with lissamine green : Grade 11
FV Corneal and conjunctival staining with lissamine green : Grade 20

Adverse events

Collected over From day 1 (basal visit) to the safety call on day 21(±2 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PRO-2010/29 (0%)0/29 (0%)21/29 (72.4%)
Most frequent other events
Most frequent other events
EventPRO-201
irritation in the area of instillationEye disorders10/29
Burning sensationEye disorders9/29
Blurred visionEye disorders7/29
Ocular hyperemiaEye disorders4/29
PruritusEye disorders3/29
TearingEye disorders3/29
Foreign body sensationEye disorders2/29
HeadacheNervous system disorders2/29
decreased visual acuityEye disorders2/29

Baseline characteristics

The manifested adverse events during the conduction of this trial were obtained during trial visits and reported in the electronic CRF, where the clinical team of the center included the information from source documents. These were previously checked by the monitor team, pharmacovigilance specialist, and the medical specialist part of the sponsor's crew to verify concordance with what was stipulated in the protocol.

Age, Categorical
Age, Categorical(Participants)PRO-201
<=18 years0
Between 18 and 65 years29
>=65 years0
Age, Continuous
Age, Continuous(years)PRO-201
Mean22.033 ± 3.61
Sex: Female, Male
Sex: Female, Male(Participants)PRO-201
Female19
Male10
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)PRO-201
Region of Enrollment
Region of Enrollment(participants)PRO-201
Mexico29
Intraocular pressure (IOP)
Intraocular pressure (IOP)(mmhg)PRO-201
Mean14.67 ± 2.67
08

Study locations

1 site
  • IIMET Investigación e Innovación en Medicina Traslacional
    Guadalajara, Jalisco 44610, Mexico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Dec 2022, 4 months.

Results were first posted in Feb 2026, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2022
First posted
Jul 22, 2022
StartActual
Aug 20, 2022
Primary completionActual
Dec 26, 2022
CompletionActual
Dec 26, 2022
Results first posted
Feb 5, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05470881
Responsible party
Sponsor
First posted
Jul 22, 2022
Start date
Aug 20, 2022
Primary completion
Dec 26, 2022
Completion
Dec 26, 2022
Results posted
Feb 5, 2026
Last update
Feb 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion